Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
Emtricitabine - NIH adult HIV guidance
Product / population
NIH adult/adolescent ART table; professional guidance differs from standalone EMTRIVA labeling.
Renal method
Cockcroft-Gault creatinine clearance (CrCl), mL/min; not BSA-indexed laboratory eGFR.
Source revision
Source revision date not established in selected retrieval.
Retrieved
2026-09-08
Local review status
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
EMTRIVA versus NIH: explicit renal schedule deviation
The standalone capsule/solution label reduces dosing at selected bands where NIH uses no adjustment. NIH footnote b explains its incorporation of some fixed-dose-product guidance.
What to reconcile: Choose and document one applicable institutional/specialist approach. Do not average schedules or silently relabel the NIH approach as the standalone product label.
NIH / HHS Adult and Adolescent Antiretroviral Guidelines Panel · NIH adult/adolescent ART table; professional guidance differs from standalone EMTRIVA labeling.
Renal method: Cockcroft-Gault creatinine clearance (CrCl), mL/min; not BSA-indexed laboratory eGFR. Source date: Source revision date not established in selected retrieval. Retrieved: 2026-09-08
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
NIH lists the usual adult FTC dose as a 200 mg capsule daily or 240 mg (24 mL) oral solution daily. It uses no adjustment at CrCl 30 to 49 mL/min and in hemodialysis, with administration after dialysis. Footnote b explicitly incorporates dosing from certain FTC-containing fixed-dose products despite the standalone EMTRIVA label's reductions. Keep this expert-guidance approach separate from the label schedule; it is not a silent label correction or universal pediatric rule.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.